Sanofi-aventis 2006: In a Difficult Environment, Another Year of
MSN MoneyCentral - Saredutant (SR48968) is a NK2 receptor antagonist in phase III for the treatment of Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD). Four phase III studies (two studies statistically significant, two studies not statistically
Source: news.moneycentral.msn.com
Click here for more information about anxiety and depression new or old
<< Home